Business
Press Release Feb 28 2026
Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 28, 2026, titled "Zydus receives final approvals from USFDA for Ivermectin Tablets USP, 3 mg and Dapsone Tablets USP, 25 mg and 100 mg".
About this update from Zydus Lifesciences Limited
Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 28, 2026, titled "Zydus receives final approvals from USFDA for Ivermectin Tablets USP, 3 mg and Dapsone Tablets USP, 25 mg and 100 mg". View Attachment
View stock analysis, news, and events for Zydus Lifesciences Limited